The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87)
Nanoforming Biologics And GLP-1s: From I.V
"I think there's not enough research done on the contaminants in them." In a statement, the TGA said: "Unapproved peptides have not been assessed by the TGA for safety, quality or efficacy
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
One positive is i sleep better